Prognostic role of microRNAs in breast cancer: A systematic review

Eleni Zografos, Flora Zagouri, Despoina Kalapanida, Roubini Zakopoulou, Anastasios Kyriazoglou, Kleoniki Apostolidou, Maria Gazouli and Meletios-Athanasios Dimopoulos

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:7156-7178. https://doi.org/10.18632/oncotarget.27327

Metrics: PDF 1837 views  |   Full Text 3851 views  |   ?  


Eleni Zografos1, Flora Zagouri2, Despoina Kalapanida2, Roubini Zakopoulou2, Anastasios Kyriazoglou2, Kleoniki Apostolidou2, Maria Gazouli1 and Meletios-Athanasios Dimopoulos2

1 Department of Basic Medical Sciences, Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

2 Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Correspondence to:

Eleni Zografos,email: el_[email protected]

Keywords: breast cancer; microRNAs; prognosis; biomarkers

Received: August 07, 2019     Accepted: October 26, 2019     Published: December 24, 2019


MicroRNAs (miRNAs) have been found to play an important role in breast cancer, functioning either as potential oncogenes or tumor suppressor genes, but their role in the prognosis of patients remains unclear. The aim of the present review study is to highlight recent preclinical and clinical studies performed on both circulating and tissue-specific miRNAs and their potential role as prognostic markers in breast cancer. We systematically searched the PubMed database to explore the prognostic value of miRNAs in breast cancer. After performing the literature search and review, 117 eligible studies were identified. We found that 110 aberrantly expressed miRNAs have been associated with prognosis in breast cancer. In conclusion, the collective data presented in this review indicate that miRNAs could serve as novel prognostic tools in breast cancer, while the clinical application of these findings has yet to be verified.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27327